Compare Invesco DB Commodity Index Tracking Fund (DBC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs 10X Genomics Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.8 (market cap $1.93B), while 10X Genomics Inc trades at $80.1 (market cap $9.92B). The key difference: 10X Genomics Inc is far larger — about 5.1× Invesco DB Commodity Index Tracking Fund's market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 61 Days and 10X Genomics Inc for 92 Days on average.
| DBC | TXG | |
|---|---|---|
Market Cap | $1.93B | $9.92B |
Volume | 569,977 | 9,372,166 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $97.74 |
52-Week Low | $22.07 | $11.48 |
Typical Hold Time | 61 Days | 92 Days |
Enterprise Value | — | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% on the day, with a bullish technical signal from moving averages. The company reported $82.59M in revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Cash flow from operations was strong at $431.54M, contributing to a healthy balance sheet with $1.28B in shareholder equity and minimal debt.
The outlook appears favorable with positive earnings momentum and robust operational cash flow. Key risks include revenue volatility, as seen in historical fluctuations, and dependence on commodity market conditions. Analyst sentiment is constructive given the bullish technical indicators and improved financial performance.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
